Eden Innovations Ltd trimmed its loss to $5 million in FY2026 while erasing bank debt and converting loans into equity, supported by property sales and capital raises.
- 19% revenue decline to $1.98 million
- Loss after tax narrowed 30% to $5 million
- Bank debt fully repaid and related party loans converted
- Property sale in Augusta, Georgia generated $4.25 million gain
- Post-year EdenCrete® trial results show strength gains
Financial Performance Highlights and Revenue Mix
Eden Innovations Ltd (ASX:EDE) reported a 19% drop in revenue to $1.98 million for the year ended 30 June 2026, reflecting softer sales of its EdenCrete® concrete additive amid timing fluctuations in bulk purchases. However, OptiBlend® sales and services grew 10%, buoyed by new demand from the US data centre back-up power market. Despite the revenue dip, the company reduced its loss after tax by 30% to $5 million, an improvement partly driven by a one-off gain on the sale of a property in Augusta, Georgia.
Balance Sheet Transformation and Debt Elimination
The standout development was Eden’s overhaul of its balance sheet. The company sold the Augusta property for approximately $7.6 million (US$5 million), generating a gain of $4.25 million. Proceeds were used to reduce and ultimately repay the secured iBorrow REIT facility, eliminating the group’s bank debt by January 2026. This was supported by a $2.2 million convertible loan from strategic investor 7 Enterprises Pty Ltd, converted into shares early in 2026. Additionally, nearly $7.5 million of loans from entities linked to directors were converted into equity, alongside a successful entitlement offer and placements raising over $8 million. These moves ended the company’s reliance on high-cost debt and lifted net tangible assets per share to $0.0253 from a negative position the prior year.
Operational and Leadership Developments
Operationally, all revenue was generated through Eden’s US and Indian subsidiaries. The company appointed Dr Allan Godsk Larsen as Managing Director in February 2026, signalling a leadership refresh concurrent with its financial restructuring. Eden also completed a 20-for-1 share consolidation in August 2025, streamlining its capital structure ahead of the equity raises.
Post-Year-End Progress on EdenCrete®
Post balance date, Eden announced positive laboratory trial results from India’s Central Road Research Institute for its EdenCrete® Pz7 product, showing up to 19% increases in compressive strength and 28% reductions in abrasion loss compared to control mixes. This validation supports the product’s performance claims and may bolster commercial uptake. Shortly after, the company revealed that Amrize requested four additional bulk EdenCrete® installations at plants in Texas, Minnesota, and the greater Toronto area, expanding its North American footprint. These developments follow Eden’s recent strategic capital raises and operational focus on scaling EdenCrete® installations across key markets EdenCrete® Pz7 installations expand and New EdenCrete®Pz7 installations.
Dividend Policy and Forward Considerations
No dividends were declared or paid during the year, consistent with Eden’s focus on strengthening its balance sheet and funding growth initiatives. The company ended FY2026 with $5.4 million in cash, a substantial increase from $563,000 a year earlier, reflecting improved liquidity. While the company has eliminated interest-bearing debt, it continues to report losses and negative operating cash flow, highlighting the ongoing challenge of achieving sustainable profitability amid growth investments.
Bottom Line?
Eden Innovations has materially strengthened its financial footing by eradicating bank debt and converting loans to equity, but the path to profitability depends on commercialising EdenCrete® at scale.
Questions in the middle?
- Will Eden’s expanded EdenCrete® installations translate into sustained revenue growth?
- How will the company manage cash flow given ongoing operating losses despite balance sheet improvements?
- What impact will Dr Allan Godsk Larsen’s leadership have on commercial execution and cost control?